Quantifying disease severity in amanitin-intoxicated patients by fusing common laboratory values.
4 affiliations
- 1Institute for Laboratory Animal Science, Hannover Medical School, Hanover, Germany.
- 2Institute of Immunology, Hannover Medical School, Hanover, Germany.
- 3Institute of Clinical Chemistry and Laboratory Medicine, Hannover Medical School, Hanover, Germany.
- 4Institute of Medical Statistics, RWTH Aachen University Hospital, Aachen, Germany.
Abstract
Introduction
Amanitin intoxication following ingestion of amatoxin-containing mushrooms can cause acute hepatic and renal failure. We evaluated the feasibility of using an adapted Patient Vital Status (PVS) fusion score derived from routine laboratory parameters to assess disease severity in amanitin-intoxicated patients.Methods
In this retrospective single-center pilot study (2023-2024), pseudonymized laboratory data from 16 adults with urine-confirmed amanitin intoxication and 12 control patients with comparable laboratory measurements were analyzed. PVS was calculated using prothrombin time (Quick), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and lactate dehydrogenase (LDH), with predefined normal values and an intermediate-care reference group (n = 5) for severity scaling.Results
Intoxicated patients had significantly higher maximum and mean PVS values than controls (PVSmax: 0.75 ± 0.54 vs. 0.12 ± 0.04; PVSmean: 0.32 ± 0.25 vs. 0.05 ± 0.02; mean ± standard deviation; both p < 0.001). Exploratory k-means clustering (k = 4) yielded four descriptive severity groups. The most severely affected patient reached a maximum PVS of 1.91 (ALT 10,373 U/L; AST 8,776 U/L; Quick 26.7%). Among patients with a matched ingestion time, the median time to peak PVS was 3.03 days (Q1-Q3, 2.13-3.54; n = 15). PVS was positively associated with Model for End-Stage Liver Disease (MELD) scores (p < 0.001). One patient died (last PVS 1.34). Urinary amanitin concentrations were not significantly associated with severity metrics.Discussion
These findings support the feasibility of adapting PVS for longitudinal laboratory-based severity assessment in amanitin intoxication. Given the exploratory nature and limited sample size of this pilot study, validation in larger prospective cohorts is warranted.
Related
- Quantifying Reproducibility of Common Laboratory Tests in a Tertiary Care Hospital for More Realistic Synthetic Data in Machine Learning
- Clinical, laboratory, operative, and appendiceal morphometric correlates of histopathological appendicitis severity: A retrospective cohort study from Palestine
- Integrating Anti-SARS-CoV-2 Spike Protein IgG, IL-6, and NK Cell Percentage with Routine Laboratory Markers for COVID-19 Severity Assessment: Development and Validation of the CORIS Nomogram.
- Sulforaphane Alleviates α-Amanitin-Induced Liver Injury by Modulating Pink1-Parkin Pathway
- CATECHIN AMELIORATES MARKERS OF HEPATIC DAMAGE AND MODULATES IMMUNE RESPONSES IN CARBON TETRACHLORIDE-INTOXICATED RATS
BibTeX
@article{ohland2026quantifying,
title = {{Quantifying disease severity in amanitin-intoxicated patients by fusing common laboratory values.}},
author = {Philipp L S Ohland and Stephan Halle and Korbinian Brand and André Bleich and Steven R Talbot},
journal = {Frontiers in toxicology},
year = {2026},
month = oct,
doi = {10.3389/ftox.2026.1995921},
url = {https://europepmc.org/article/MED/42948806},
note = {CC BY},
}
RIS
TY - JOUR
TI - Quantifying disease severity in amanitin-intoxicated patients by fusing common laboratory values.
AU - Philipp L S Ohland
AU - Stephan Halle
AU - Korbinian Brand
AU - André Bleich
AU - Steven R Talbot
PY - 2026
DA - 2026/10/14
JO - Frontiers in toxicology
DO - 10.3389/ftox.2026.1995921
UR - https://europepmc.org/article/MED/42948806
AB - Introduction Amanitin intoxication following ingestion of amatoxin-containing mushrooms can cause acute hepatic and renal failure. We evaluated the feasibility of using an adapted Patient Vital Status (PVS) fusion score derived from routine laboratory parameters to assess disease severity in amanitin-intoxicated patients.Methods In this retrospective single-center pilot study (2023-2024), pseudonymized laboratory data from 16 adults with urine-confirmed amanitin intoxication and 12 control patients with comparable laboratory measurements were analyzed. PVS was calculated using prothrombin time (Quick), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and lactate dehydrogenase (LDH), with predefined normal values and an intermediate-care reference group (n = 5) for severity scaling.Results Intoxicated patients had significantly higher maximum and mean PVS values than controls (PVSmax: 0.75 ± 0.54 vs. 0.12 ± 0.04; PVSmean: 0.32 ± 0.25 vs. 0.05 ± 0.02; mean ± standard deviation; both p < 0.001). Exploratory k-means clustering (k = 4) yielded four descriptive severity groups. The most severely affected patient reached a maximum PVS of 1.91 (ALT 10,373 U/L; AST 8,776 U/L; Quick 26.7%). Among patients with a matched ingestion time, the median time to peak PVS was 3.03 days (Q1-Q3, 2.13-3.54; n = 15). PVS was positively associated with Model for End-Stage Liver Disease (MELD) scores (p < 0.001). One patient died (last PVS 1.34). Urinary amanitin concentrations were not significantly associated with severity metrics.Discussion These findings support the feasibility of adapting PVS for longitudinal laboratory-based severity assessment in amanitin intoxication. Given the exploratory nature and limited sample size of this pilot study, validation in larger prospective cohorts is warranted.
SN - 2673-3080
ER -